I CONSENSO BRASILEIRO DE TRATAMENTO MULTIDISCIPLINAR DE METÁSTASE HEPÁTICA COLORRETAIS MÓDULO 2: MANEJO DAS METÁSTASES RESSECÁVEIS

We report a case of a patient with primary malignant lymphoma of the liver, of B-cell origin, who underwent surgical treatment followed by sys- temic chemotherapy..

Recently, a Phase II study presented at American Society of Clinical Oncology (ASCO) 2013 enrolled patients with TNBC to receive a metronomic neoadjuvant chemotherapy regimen

We should also mention that immunotherapy with rituximab should be part of chemotherapy treatment for a better survival prognosis in patients affected by this

Thus, it can be said that the intervention was effective in reducing hyperphosphatemia and that the more informed patients are about their disease and treatment, the better

Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection. The results of a prospective

While both retrospective and observational studies have reported improved survival outcomes for patients with metastatic (M1) disease who undergo primary tumor treatment relative

After neoadjuvant chemotherapy, the patient underwent surgical resection of the mass, followed by pathological examination, which confirmed a primary mediastinal yolk sac tumor,

prognostic factors in the survival of 24 patients diagnosed with primary non-metastatic osteosarcoma with a poor response to neoadjuvant chemotherapy and found that